Treat identity, inspection evidence and product sourcing as separate checks. FDA’s outsourcing-facility register is facility-specific and does not include state-board actions; FDA also explains that a Form 483 records observations and is not itself a final agency determination of a violation. (fda.gov)
Answers stay in this session unless you choose to save. No account needed.
Evidence to attach: a GLP-1 Supplier Evidence Audit showing each claim, supporting record, source date, reviewer conclusion and open action.
Where DSCSA applies, document the responsible entity and any exemption relied upon. FDA’s exemption framework is specific to covered requirements and qualifying entities; do not treat a claimed exemption as a blanket release from traceability responsibilities. (fda.gov)
If you score 0–1: request the missing evidence and obtain qualified review. Missing public information should remain unknown, not become either a clean bill of health or an adverse finding.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act